Hikma Pharmaceuticals PLC said Monday the chief executive of the U.S. business Michael Raya is retiring after 25 years on the job amid organizational changes at the division.
From July 1, the U.S. business will be organized into two entities–U.S. Generics Division and U.S. Injectables Division–both of which will report to the chairman and the chief executive officer of Hikma, the company said.
The company said it is doing do because it wants to “reflect its enhanced U.S. market positioning and to better align with the global Hikma organization.”
By Olga Cotaga
Source: Market Watch
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.